Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Frail Elderly | 49 | 2024 | 693 | 8.300 |
Why?
|
Geriatric Assessment | 47 | 2024 | 1372 | 7.750 |
Why?
|
Activities of Daily Living | 24 | 2024 | 2419 | 3.430 |
Why?
|
Dementia | 14 | 2024 | 2518 | 2.980 |
Why?
|
Independent Living | 15 | 2023 | 568 | 2.940 |
Why?
|
Medicare | 51 | 2024 | 6566 | 2.310 |
Why?
|
Skilled Nursing Facilities | 6 | 2023 | 372 | 2.210 |
Why?
|
Aged | 171 | 2024 | 163288 | 2.090 |
Why?
|
Heart Valve Prosthesis Implantation | 9 | 2021 | 1537 | 1.870 |
Why?
|
Antipsychotic Agents | 7 | 2023 | 3057 | 1.820 |
Why?
|
Pneumonia | 5 | 2022 | 2133 | 1.790 |
Why?
|
Hypertension | 17 | 2023 | 8479 | 1.700 |
Why?
|
Sarcopenia | 5 | 2020 | 368 | 1.670 |
Why?
|
Aortic Valve Stenosis | 14 | 2021 | 1965 | 1.660 |
Why?
|
Insurance Claim Review | 5 | 2020 | 720 | 1.660 |
Why?
|
Republic of Korea | 12 | 2023 | 538 | 1.610 |
Why?
|
Atrial Fibrillation | 10 | 2023 | 5035 | 1.470 |
Why?
|
Delirium | 6 | 2022 | 1610 | 1.410 |
Why?
|
Cardiovascular Diseases | 19 | 2023 | 15160 | 1.390 |
Why?
|
Antihypertensive Agents | 12 | 2023 | 2047 | 1.310 |
Why?
|
Aortic Valve | 11 | 2021 | 1924 | 1.270 |
Why?
|
Blood Pressure | 16 | 2023 | 8551 | 1.250 |
Why?
|
Blood Pressure Determination | 6 | 2023 | 633 | 1.210 |
Why?
|
Patient Discharge | 9 | 2023 | 3318 | 1.210 |
Why?
|
Heart Valve Prosthesis | 4 | 2020 | 1490 | 1.170 |
Why?
|
United States | 77 | 2024 | 69872 | 1.160 |
Why?
|
Aged, 80 and over | 64 | 2024 | 57776 | 1.150 |
Why?
|
Humans | 228 | 2024 | 744366 | 1.120 |
Why?
|
Erectile Dysfunction | 2 | 2020 | 461 | 1.020 |
Why?
|
Male | 117 | 2024 | 350115 | 1.000 |
Why?
|
Female | 120 | 2024 | 380193 | 0.970 |
Why?
|
Heart Failure | 11 | 2023 | 10895 | 0.950 |
Why?
|
Health Status Indicators | 2 | 2020 | 970 | 0.950 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2023 | 293 | 0.940 |
Why?
|
Recovery of Function | 5 | 2021 | 2926 | 0.920 |
Why?
|
Disability Evaluation | 5 | 2016 | 1828 | 0.910 |
Why?
|
International Classification of Diseases | 4 | 2021 | 867 | 0.910 |
Why?
|
Warfarin | 6 | 2023 | 1497 | 0.860 |
Why?
|
Disabled Persons | 5 | 2019 | 1212 | 0.850 |
Why?
|
Myocardial Infarction | 10 | 2023 | 11718 | 0.850 |
Why?
|
Subacute Care | 2 | 2023 | 168 | 0.840 |
Why?
|
Decision Support Techniques | 2 | 2022 | 1956 | 0.800 |
Why?
|
Sulfonylurea Compounds | 3 | 2023 | 205 | 0.780 |
Why?
|
Cardiac Surgical Procedures | 5 | 2023 | 3537 | 0.760 |
Why?
|
Coronary Artery Disease | 7 | 2023 | 6486 | 0.730 |
Why?
|
Diabetes Mellitus, Type 2 | 11 | 2023 | 11726 | 0.730 |
Why?
|
Retrospective Studies | 43 | 2023 | 77460 | 0.710 |
Why?
|
Hospital Records | 1 | 2019 | 95 | 0.700 |
Why?
|
Hearing Aids | 1 | 2020 | 55 | 0.700 |
Why?
|
Vascular Malformations | 2 | 2015 | 454 | 0.680 |
Why?
|
Risk Assessment | 22 | 2023 | 23336 | 0.670 |
Why?
|
Fractures, Bone | 5 | 2023 | 1947 | 0.670 |
Why?
|
Hospital Mortality | 7 | 2023 | 5316 | 0.670 |
Why?
|
Dexmedetomidine | 1 | 2023 | 315 | 0.670 |
Why?
|
Pemphigoid, Bullous | 1 | 2020 | 109 | 0.660 |
Why?
|
Survival Rate | 11 | 2022 | 12788 | 0.660 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2023 | 2073 | 0.660 |
Why?
|
Aging | 8 | 2023 | 8664 | 0.660 |
Why?
|
Cognition Disorders | 6 | 2016 | 4043 | 0.640 |
Why?
|
Coronary Artery Bypass | 5 | 2023 | 2288 | 0.640 |
Why?
|
Risk Factors | 43 | 2023 | 72296 | 0.640 |
Why?
|
Prospective Studies | 30 | 2022 | 53290 | 0.640 |
Why?
|
Cohort Studies | 21 | 2023 | 40559 | 0.620 |
Why?
|
Quality of Life | 11 | 2023 | 12802 | 0.610 |
Why?
|
Ischemic Attack, Transient | 1 | 2023 | 935 | 0.610 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 465 | 0.610 |
Why?
|
Propensity Score | 6 | 2021 | 1781 | 0.610 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2200 | 0.590 |
Why?
|
Patient-Centered Care | 2 | 2018 | 1438 | 0.590 |
Why?
|
Accidental Falls | 6 | 2023 | 1062 | 0.570 |
Why?
|
Anticoagulants | 7 | 2023 | 4600 | 0.560 |
Why?
|
Pravastatin | 1 | 2018 | 395 | 0.560 |
Why?
|
Veterans | 7 | 2023 | 2519 | 0.560 |
Why?
|
Nursing Homes | 4 | 2023 | 1036 | 0.550 |
Why?
|
Haloperidol | 3 | 2023 | 397 | 0.550 |
Why?
|
Rural Population | 5 | 2022 | 2207 | 0.540 |
Why?
|
Postoperative Complications | 7 | 2022 | 15297 | 0.530 |
Why?
|
Cholinesterase Inhibitors | 2 | 2021 | 238 | 0.520 |
Why?
|
Retinal Diseases | 2 | 2011 | 684 | 0.510 |
Why?
|
Health Status | 3 | 2018 | 4034 | 0.500 |
Why?
|
Phenotype | 8 | 2021 | 16367 | 0.490 |
Why?
|
Thoracic Surgical Procedures | 1 | 2018 | 342 | 0.480 |
Why?
|
Polypharmacy | 3 | 2022 | 294 | 0.480 |
Why?
|
Vulnerable Populations | 2 | 2020 | 686 | 0.470 |
Why?
|
Cross-Sectional Studies | 16 | 2024 | 25039 | 0.460 |
Why?
|
Diphosphonates | 2 | 2016 | 623 | 0.460 |
Why?
|
Nutritional Status | 3 | 2018 | 1609 | 0.460 |
Why?
|
Mortality | 6 | 2021 | 2864 | 0.460 |
Why?
|
Ticlopidine | 2 | 2009 | 899 | 0.450 |
Why?
|
Aspirin | 2 | 2019 | 3283 | 0.440 |
Why?
|
Syncope | 2 | 2018 | 429 | 0.440 |
Why?
|
Patient Admission | 1 | 2021 | 1380 | 0.440 |
Why?
|
Patient Readmission | 4 | 2023 | 3116 | 0.440 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2023 | 1240 | 0.440 |
Why?
|
Bone Density Conservation Agents | 2 | 2022 | 772 | 0.430 |
Why?
|
Social Behavior | 1 | 2019 | 1127 | 0.430 |
Why?
|
Comorbidity | 9 | 2023 | 10388 | 0.430 |
Why?
|
Stroke | 7 | 2023 | 9981 | 0.430 |
Why?
|
Hearing Loss | 1 | 2020 | 765 | 0.430 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1637 | 0.420 |
Why?
|
Treatment Outcome | 30 | 2023 | 63107 | 0.420 |
Why?
|
Acute Kidney Injury | 2 | 2022 | 1968 | 0.420 |
Why?
|
Prognosis | 13 | 2021 | 29060 | 0.410 |
Why?
|
Life Expectancy | 2 | 2019 | 1184 | 0.410 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1425 | 0.410 |
Why?
|
Geriatrics | 1 | 2016 | 397 | 0.400 |
Why?
|
Surgical Procedures, Operative | 2 | 2020 | 1877 | 0.400 |
Why?
|
Cause of Death | 3 | 2021 | 3582 | 0.400 |
Why?
|
Pharmacoepidemiology | 1 | 2014 | 323 | 0.390 |
Why?
|
Anticholesteremic Agents | 1 | 2018 | 979 | 0.390 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.380 |
Why?
|
Prevalence | 12 | 2023 | 15221 | 0.380 |
Why?
|
Drug Utilization | 1 | 2017 | 1183 | 0.380 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6539 | 0.380 |
Why?
|
Memantine | 1 | 2011 | 100 | 0.370 |
Why?
|
Exercise | 4 | 2020 | 5615 | 0.370 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2023 | 3070 | 0.370 |
Why?
|
Dopamine Agents | 1 | 2011 | 189 | 0.370 |
Why?
|
Cognition | 6 | 2021 | 6770 | 0.370 |
Why?
|
Hospitalization | 12 | 2023 | 10259 | 0.360 |
Why?
|
Nootropic Agents | 1 | 2011 | 160 | 0.360 |
Why?
|
Seafood | 1 | 2013 | 384 | 0.360 |
Why?
|
Checklist | 1 | 2017 | 833 | 0.350 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2009 | 63 | 0.350 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1199 | 0.350 |
Why?
|
Health Status Disparities | 3 | 2019 | 1796 | 0.350 |
Why?
|
Benzethonium | 1 | 2009 | 3 | 0.350 |
Why?
|
Paromomycin | 1 | 2009 | 10 | 0.350 |
Why?
|
Hand Strength | 3 | 2021 | 448 | 0.340 |
Why?
|
Antiprotozoal Agents | 1 | 2009 | 86 | 0.330 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2716 | 0.320 |
Why?
|
Age Factors | 11 | 2021 | 18373 | 0.320 |
Why?
|
Time Factors | 13 | 2021 | 40075 | 0.320 |
Why?
|
Drug-Eluting Stents | 2 | 2019 | 753 | 0.310 |
Why?
|
Hip Fractures | 3 | 2023 | 955 | 0.310 |
Why?
|
Incidence | 9 | 2021 | 20952 | 0.310 |
Why?
|
Depression | 4 | 2023 | 7759 | 0.310 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5749 | 0.310 |
Why?
|
France | 5 | 2020 | 517 | 0.310 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2009 | 124 | 0.300 |
Why?
|
HIV Infections | 3 | 2022 | 16715 | 0.300 |
Why?
|
Adiponectin | 1 | 2013 | 1101 | 0.290 |
Why?
|
Health Services for the Aged | 1 | 2009 | 269 | 0.290 |
Why?
|
Cardiology Service, Hospital | 1 | 2008 | 246 | 0.280 |
Why?
|
Comparative Effectiveness Research | 2 | 2023 | 680 | 0.280 |
Why?
|
Stroke Volume | 6 | 2023 | 5006 | 0.280 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 195 | 0.270 |
Why?
|
Self Report | 3 | 2022 | 3553 | 0.270 |
Why?
|
Administration, Oral | 3 | 2023 | 3914 | 0.270 |
Why?
|
Severity of Illness Index | 9 | 2021 | 15535 | 0.270 |
Why?
|
Carotid Artery Diseases | 2 | 2011 | 879 | 0.270 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 7914 | 0.270 |
Why?
|
Retinal Vessels | 1 | 2011 | 772 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2021 | 9955 | 0.260 |
Why?
|
Forecasting | 1 | 2014 | 2951 | 0.250 |
Why?
|
Institutionalization | 2 | 2023 | 104 | 0.250 |
Why?
|
Carbonated Beverages | 1 | 2006 | 214 | 0.250 |
Why?
|
Odds Ratio | 7 | 2022 | 9849 | 0.250 |
Why?
|
Terminal Care | 3 | 2021 | 1694 | 0.250 |
Why?
|
Hypoglycemic Agents | 6 | 2023 | 2873 | 0.250 |
Why?
|
Preventive Health Services | 1 | 2009 | 575 | 0.240 |
Why?
|
Shock, Septic | 1 | 2011 | 775 | 0.240 |
Why?
|
Morbidity | 4 | 2023 | 1768 | 0.240 |
Why?
|
Patient Acceptance of Health Care | 3 | 2022 | 3020 | 0.240 |
Why?
|
Canada | 5 | 2021 | 2065 | 0.240 |
Why?
|
Dietary Fats | 2 | 2012 | 2016 | 0.230 |
Why?
|
Middle Aged | 26 | 2022 | 213390 | 0.230 |
Why?
|
Algorithms | 4 | 2021 | 13882 | 0.230 |
Why?
|
Coronary Disease | 1 | 2018 | 6077 | 0.230 |
Why?
|
Microcirculation | 3 | 2014 | 1287 | 0.230 |
Why?
|
Hypotension | 1 | 2009 | 884 | 0.230 |
Why?
|
Receptors, Angiotensin | 1 | 2023 | 142 | 0.220 |
Why?
|
Peripheral Vascular Diseases | 1 | 2006 | 550 | 0.220 |
Why?
|
Heart Rate | 3 | 2019 | 4092 | 0.220 |
Why?
|
Advance Care Planning | 2 | 2020 | 662 | 0.220 |
Why?
|
Cerebrovascular Disorders | 1 | 2010 | 1504 | 0.220 |
Why?
|
Survival Analysis | 7 | 2021 | 10252 | 0.210 |
Why?
|
Glaucoma | 2 | 2023 | 1159 | 0.210 |
Why?
|
Proportional Hazards Models | 8 | 2022 | 12356 | 0.210 |
Why?
|
Pyrazoles | 2 | 2023 | 1972 | 0.210 |
Why?
|
Cholesterol, HDL | 2 | 2009 | 1813 | 0.200 |
Why?
|
Models, Statistical | 2 | 2014 | 5101 | 0.200 |
Why?
|
Dietary Supplements | 2 | 2018 | 3296 | 0.200 |
Why?
|
Caffeine | 1 | 2006 | 699 | 0.200 |
Why?
|
Coffee | 1 | 2006 | 578 | 0.200 |
Why?
|
Databases, Factual | 6 | 2021 | 7730 | 0.200 |
Why?
|
Risperidone | 1 | 2023 | 383 | 0.190 |
Why?
|
Demography | 2 | 2016 | 1655 | 0.190 |
Why?
|
Colorectal Surgery | 1 | 2023 | 128 | 0.190 |
Why?
|
Stomach Neoplasms | 2 | 2021 | 1332 | 0.190 |
Why?
|
Biomedical Research | 1 | 2016 | 3309 | 0.190 |
Why?
|
Neprilysin | 1 | 2023 | 439 | 0.190 |
Why?
|
Life Style | 2 | 2009 | 3835 | 0.180 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15078 | 0.180 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2023 | 362 | 0.180 |
Why?
|
Pyridones | 2 | 2023 | 711 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3255 | 0.180 |
Why?
|
Alzheimer Disease | 3 | 2023 | 8038 | 0.180 |
Why?
|
Hemorrhage | 4 | 2023 | 3461 | 0.180 |
Why?
|
Medical Oncology | 3 | 2022 | 2267 | 0.180 |
Why?
|
Oxadiazoles | 1 | 2020 | 93 | 0.180 |
Why?
|
Consensus | 2 | 2019 | 2960 | 0.180 |
Why?
|
Embolism | 1 | 2023 | 408 | 0.180 |
Why?
|
Health Care Costs | 2 | 2023 | 3208 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11525 | 0.180 |
Why?
|
Aromatase | 1 | 2020 | 147 | 0.180 |
Why?
|
Depressive Disorder | 2 | 2011 | 3747 | 0.170 |
Why?
|
Preoperative Care | 2 | 2019 | 2251 | 0.170 |
Why?
|
Osteoporosis | 2 | 2022 | 1579 | 0.170 |
Why?
|
Decision Making | 3 | 2018 | 3888 | 0.170 |
Why?
|
Current Procedural Terminology | 1 | 2020 | 92 | 0.170 |
Why?
|
Hospitals | 2 | 2023 | 3954 | 0.170 |
Why?
|
Telephone | 1 | 2022 | 617 | 0.170 |
Why?
|
Exercise Therapy | 1 | 2006 | 904 | 0.170 |
Why?
|
Iceland | 1 | 2019 | 183 | 0.170 |
Why?
|
Trifluridine | 1 | 2019 | 29 | 0.170 |
Why?
|
Atrial Appendage | 1 | 2023 | 283 | 0.170 |
Why?
|
Research Design | 4 | 2022 | 5984 | 0.170 |
Why?
|
Vitamin D Deficiency | 1 | 2008 | 1343 | 0.160 |
Why?
|
Walking | 1 | 2006 | 1180 | 0.160 |
Why?
|
Risk | 4 | 2015 | 9688 | 0.160 |
Why?
|
Accidents, Home | 1 | 2018 | 75 | 0.160 |
Why?
|
Stents | 2 | 2019 | 3282 | 0.160 |
Why?
|
Habits | 1 | 2019 | 139 | 0.160 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 202 | 0.160 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 2355 | 0.160 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 145 | 0.160 |
Why?
|
Breast Neoplasms | 3 | 2022 | 20824 | 0.150 |
Why?
|
Health Behavior | 1 | 2009 | 2635 | 0.150 |
Why?
|
Psychotropic Drugs | 1 | 2023 | 894 | 0.150 |
Why?
|
Propanolamines | 1 | 2018 | 167 | 0.150 |
Why?
|
Osteoporotic Fractures | 1 | 2022 | 401 | 0.150 |
Why?
|
Benzodiazepines | 1 | 2023 | 1101 | 0.150 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2018 | 113 | 0.150 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 923 | 0.150 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 256 | 0.150 |
Why?
|
Critical Care | 2 | 2020 | 2647 | 0.150 |
Why?
|
Length of Stay | 3 | 2020 | 6311 | 0.150 |
Why?
|
Sex Factors | 3 | 2020 | 10400 | 0.140 |
Why?
|
Confidence Intervals | 3 | 2020 | 2971 | 0.140 |
Why?
|
Task Performance and Analysis | 1 | 2020 | 780 | 0.140 |
Why?
|
Logistic Models | 5 | 2020 | 13409 | 0.140 |
Why?
|
Postoperative Hemorrhage | 1 | 2020 | 412 | 0.140 |
Why?
|
Random Allocation | 1 | 2021 | 2428 | 0.140 |
Why?
|
Hypoglycemia | 1 | 2023 | 861 | 0.140 |
Why?
|
Residence Characteristics | 3 | 2022 | 2050 | 0.130 |
Why?
|
Natural Language Processing | 1 | 2024 | 1041 | 0.130 |
Why?
|
Systole | 2 | 2009 | 958 | 0.130 |
Why?
|
Primary Health Care | 1 | 2012 | 4557 | 0.130 |
Why?
|
Longitudinal Studies | 4 | 2019 | 13991 | 0.130 |
Why?
|
Hypnotics and Sedatives | 1 | 2023 | 1162 | 0.130 |
Why?
|
Evidence-Based Medicine | 2 | 2018 | 3611 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3154 | 0.130 |
Why?
|
Nutrition Assessment | 1 | 2018 | 723 | 0.130 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 345 | 0.130 |
Why?
|
Vitamin D | 1 | 2008 | 3224 | 0.120 |
Why?
|
Acute Coronary Syndrome | 1 | 2008 | 2337 | 0.120 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 694 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 670 | 0.120 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5181 | 0.120 |
Why?
|
Femoral Artery | 1 | 2018 | 845 | 0.120 |
Why?
|
Bronchi | 1 | 2018 | 840 | 0.120 |
Why?
|
Immunotherapy | 2 | 2021 | 4446 | 0.120 |
Why?
|
Respiratory Function Tests | 1 | 2018 | 1617 | 0.120 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 154 | 0.120 |
Why?
|
Health Expenditures | 3 | 2023 | 2349 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3480 | 0.120 |
Why?
|
Anticonvulsants | 1 | 2023 | 1916 | 0.110 |
Why?
|
Electrocardiography | 2 | 2019 | 6442 | 0.110 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2021 | 340 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.110 |
Why?
|
Europe | 1 | 2019 | 3338 | 0.110 |
Why?
|
Socioeconomic Factors | 4 | 2022 | 7785 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 850 | 0.110 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7182 | 0.110 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6773 | 0.110 |
Why?
|
Endothelial Cells | 1 | 2005 | 3486 | 0.110 |
Why?
|
Quality Indicators, Health Care | 2 | 2020 | 1831 | 0.110 |
Why?
|
Exercise Tolerance | 1 | 2017 | 768 | 0.110 |
Why?
|
Macular Degeneration | 1 | 2020 | 980 | 0.110 |
Why?
|
Lung Neoplasms | 4 | 2022 | 13104 | 0.110 |
Why?
|
Health Surveys | 3 | 2019 | 4036 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2022 | 5077 | 0.110 |
Why?
|
Stem Cells | 1 | 2005 | 3567 | 0.110 |
Why?
|
Mobility Limitation | 1 | 2016 | 409 | 0.110 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39052 | 0.110 |
Why?
|
Trachea | 1 | 2018 | 1076 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3135 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3242 | 0.100 |
Why?
|
Malnutrition | 1 | 2018 | 625 | 0.100 |
Why?
|
Neuropsychological Tests | 3 | 2015 | 6994 | 0.100 |
Why?
|
Esophageal Neoplasms | 1 | 2021 | 1585 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2282 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1460 | 0.100 |
Why?
|
Antidepressive Agents | 1 | 2023 | 2838 | 0.100 |
Why?
|
Postoperative Period | 2 | 2021 | 1842 | 0.100 |
Why?
|
Exercise Test | 1 | 2018 | 2073 | 0.090 |
Why?
|
Placebos | 1 | 2015 | 1676 | 0.090 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 367 | 0.090 |
Why?
|
Lower Extremity | 1 | 2018 | 1158 | 0.090 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1832 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8385 | 0.090 |
Why?
|
Quality Improvement | 2 | 2022 | 3749 | 0.090 |
Why?
|
Neoplasms | 4 | 2022 | 21696 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2488 | 0.090 |
Why?
|
Pain | 2 | 2023 | 4988 | 0.090 |
Why?
|
Adaptation, Physiological | 1 | 2016 | 1312 | 0.090 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 2212 | 0.090 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 245 | 0.090 |
Why?
|
Selection Bias | 1 | 2011 | 371 | 0.080 |
Why?
|
Adult | 10 | 2022 | 214052 | 0.080 |
Why?
|
Interviews as Topic | 1 | 2016 | 2539 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 889 | 0.080 |
Why?
|
Sweet Syndrome | 1 | 2009 | 47 | 0.080 |
Why?
|
Imidazoles | 1 | 2015 | 1206 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2727 | 0.080 |
Why?
|
Massachusetts | 1 | 2021 | 8662 | 0.080 |
Why?
|
Heart Diseases | 1 | 2021 | 2789 | 0.080 |
Why?
|
Pennsylvania | 1 | 2009 | 613 | 0.080 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2008 | 93 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1584 | 0.080 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2018 | 6036 | 0.080 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 236 | 0.080 |
Why?
|
Urban Population | 1 | 2016 | 2022 | 0.080 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2011 | 469 | 0.080 |
Why?
|
Diastole | 1 | 2009 | 791 | 0.070 |
Why?
|
Abdominal Fat | 1 | 2009 | 223 | 0.070 |
Why?
|
Hospitals, Rural | 1 | 2008 | 172 | 0.070 |
Why?
|
Poverty | 1 | 2018 | 2660 | 0.070 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 2542 | 0.070 |
Why?
|
Leptin | 1 | 2015 | 1600 | 0.070 |
Why?
|
Hospitals, Urban | 1 | 2008 | 499 | 0.070 |
Why?
|
Employment | 1 | 2013 | 1132 | 0.070 |
Why?
|
Body Composition | 1 | 2016 | 2402 | 0.070 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1420 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2736 | 0.070 |
Why?
|
Pentoxifylline | 1 | 2006 | 55 | 0.070 |
Why?
|
Memory | 2 | 2013 | 2174 | 0.070 |
Why?
|
PPAR gamma | 1 | 2009 | 493 | 0.070 |
Why?
|
Sweden | 1 | 2009 | 1341 | 0.070 |
Why?
|
Eating | 1 | 2013 | 1536 | 0.070 |
Why?
|
Aftercare | 2 | 2023 | 870 | 0.070 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2006 | 227 | 0.070 |
Why?
|
Patient Compliance | 1 | 2016 | 2684 | 0.070 |
Why?
|
Gene Expression | 1 | 2018 | 7798 | 0.070 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3677 | 0.060 |
Why?
|
Lung | 1 | 2023 | 9857 | 0.060 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2007 | 546 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2011 | 1406 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2540 | 0.060 |
Why?
|
Blood Glucose | 2 | 2009 | 6254 | 0.060 |
Why?
|
Community Health Services | 1 | 2009 | 650 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1222 | 0.060 |
Why?
|
Vasodilation | 1 | 2008 | 944 | 0.060 |
Why?
|
Thiazides | 1 | 2023 | 18 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1186 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2021 | 4468 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14723 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4671 | 0.060 |
Why?
|
Antigens, CD34 | 1 | 2005 | 659 | 0.060 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 648 | 0.060 |
Why?
|
Intermittent Claudication | 1 | 2006 | 309 | 0.060 |
Why?
|
Amlodipine | 1 | 2023 | 83 | 0.060 |
Why?
|
Women's Health | 1 | 2013 | 2034 | 0.060 |
Why?
|
Smoking | 2 | 2011 | 8987 | 0.060 |
Why?
|
Diabetic Angiopathies | 1 | 2008 | 818 | 0.060 |
Why?
|
Social Class | 2 | 2022 | 1997 | 0.060 |
Why?
|
Body Mass Index | 4 | 2018 | 12721 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2020 | 21748 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2020 | 2373 | 0.050 |
Why?
|
Sleep Deprivation | 1 | 2009 | 832 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 849 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 5263 | 0.050 |
Why?
|
Autonomic Nervous System | 1 | 2006 | 672 | 0.050 |
Why?
|
Transportation | 1 | 2022 | 214 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6489 | 0.050 |
Why?
|
Dexamethasone | 2 | 2023 | 1951 | 0.050 |
Why?
|
Tetrazoles | 1 | 2006 | 835 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12244 | 0.050 |
Why?
|
Glucose | 2 | 2023 | 4398 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5511 | 0.040 |
Why?
|
Obesity | 2 | 2015 | 12746 | 0.040 |
Why?
|
Fatty Acids | 1 | 2007 | 1809 | 0.040 |
Why?
|
Homes for the Aged | 1 | 2021 | 260 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7658 | 0.040 |
Why?
|
Decision Trees | 1 | 2021 | 506 | 0.040 |
Why?
|
Thymine | 1 | 2019 | 68 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5692 | 0.040 |
Why?
|
Intravitreal Injections | 1 | 2020 | 344 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19905 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2009 | 1352 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2011 | 2400 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 275 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 572 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 623 | 0.040 |
Why?
|
New York | 1 | 2020 | 886 | 0.040 |
Why?
|
Lipids | 1 | 2008 | 3307 | 0.040 |
Why?
|
Intensive Care Units | 2 | 2020 | 3680 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1516 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 875 | 0.040 |
Why?
|
Absorbable Implants | 1 | 2019 | 342 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 342 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3778 | 0.040 |
Why?
|
Aminopyridines | 1 | 2020 | 542 | 0.040 |
Why?
|
Public Health | 1 | 2009 | 2602 | 0.030 |
Why?
|
Environment | 1 | 2022 | 1123 | 0.030 |
Why?
|
Acute Disease | 1 | 2007 | 7147 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 490 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1131 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4459 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 977 | 0.030 |
Why?
|
North America | 1 | 2019 | 1249 | 0.030 |
Why?
|
Sodium | 1 | 2021 | 1622 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2020 | 565 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 826 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2020 | 850 | 0.030 |
Why?
|
Child | 1 | 2023 | 77709 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 3922 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2017 | 601 | 0.030 |
Why?
|
Probability | 1 | 2020 | 2506 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2029 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2166 | 0.030 |
Why?
|
Area Under Curve | 1 | 2018 | 1655 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 1958 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2008 | 4245 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1677 | 0.030 |
Why?
|
Estrogens | 1 | 2020 | 1566 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1038 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2023 | 2760 | 0.030 |
Why?
|
Polymers | 1 | 2019 | 1621 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12025 | 0.030 |
Why?
|
Sirolimus | 1 | 2019 | 1565 | 0.030 |
Why?
|
Caregivers | 1 | 2023 | 2095 | 0.020 |
Why?
|
Medication Adherence | 1 | 2022 | 2063 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2020 | 2417 | 0.020 |
Why?
|
Women | 1 | 2012 | 230 | 0.020 |
Why?
|
Postural Balance | 1 | 2015 | 620 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2038 | 0.020 |
Why?
|
Korea | 1 | 2009 | 99 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2020 | 3511 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6582 | 0.020 |
Why?
|
Inpatients | 1 | 2020 | 2518 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 1534 | 0.020 |
Why?
|
Young Adult | 3 | 2009 | 56429 | 0.020 |
Why?
|
Prednisolone | 1 | 2009 | 334 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2670 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3219 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 35425 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 2385 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2725 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3666 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13693 | 0.020 |
Why?
|
Thiazolidinediones | 1 | 2009 | 476 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3707 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5135 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3143 | 0.020 |
Why?
|
Waist Circumference | 1 | 2009 | 917 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6459 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5321 | 0.020 |
Why?
|
Chronic Disease | 1 | 2019 | 9145 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4687 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4262 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 25628 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 1602 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5534 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9240 | 0.010 |
Why?
|
Triglycerides | 1 | 2009 | 2453 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2618 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9312 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2009 | 2108 | 0.010 |
Why?
|
Ultrasonography | 1 | 2008 | 5984 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2008 | 3864 | 0.010 |
Why?
|
Heart | 1 | 2006 | 4464 | 0.010 |
Why?
|